Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase
暂无分享,去创建一个
Zi-Fan Yu | Maurizio Scarpa | Paul Harmatz | Roberto Giugliani | Kenneth I. Berger | Michael Beck | Robert Steiner | Barbara Plecko | P. Kaplan | K. Hardy | R. Steiner | R. Giugliani | J. E. Wraith | B. Plecko | J. Hopwood | E. Teles | K. Berger | C. Whitley | P. Harmatz | N. Guffon | D. Ketteridge | M. Scarpa | M. Beck | I. Schwartz | Nathalie Guffon | John J. Hopwood | Chester B Whitley | Ida Vanessa D. Schwartz | Elisa Leão Teles | M. Clara Sá Miranda | J. Edmond Wraith | Laila Arash | David Ketteridge | Paige Kaplan | Stuart J. Swiedler | Karen Hardy | Celeste Decker | S. Swiedler | C. Decker | Zi-Fan Yu | Laila Arash | M. C. Miranda | M. C. S. Miranda | Zi‐Fan Yu | J. Hopwood | Ida Vanessa D. Schwartz | Chester B Whitley | Kenneth I. Berger
[1] D. Fairclough,et al. Spirometry and chest wall dimensions in achondroplasia. , 1988, Chest.
[2] A. Buist. Standardization of spirometry. , 1987, The American review of respiratory disease.
[3] D. F. Rochester,et al. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. , 1983, Thorax.
[4] A. Miller,et al. Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.
[5] P. Kaplan,et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). , 2004, The Journal of pediatrics.
[6] A. Coates,et al. Determination of maximal voluntary ventilation in children with cystic fibrosis , 2003, Pediatric pulmonology.
[7] R. Giugliani,et al. Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase , 2005, Pediatrics.
[8] D. Fairclough,et al. The lungs and airways in achondroplasia. Do little people have little lungs? , 1990, Chest.
[9] Joseph Muenzer,et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). , 2004, The Journal of pediatrics.
[10] F. Mastaglia,et al. Respiratory muscle function and ventilatory control. I in patients with motor neurone disease. II in patients with myotonic dystrophy. , 1982, The Quarterly journal of medicine.
[11] Albert Francis Blakeslee,et al. Department of Genetics , 1941 .
[12] J. Hankinson,et al. Interpretative strategies for lung function tests , 2005, European Respiratory Journal.
[13] Buist As. Standardization of spirometry. , 1987 .
[14] R. Giugliani,et al. Management Guidelines for Mucopolysaccharidosis VI , 2007, Pediatrics.
[15] L. Kager,et al. Fibrinolytic Activity in Plasma of Newborn Infants , 1964, Acta paediatrica.
[16] John L. Hankinson,et al. Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.
[17] M. Rosenthal,et al. Lung function in white children aged 4 to 19 years: I--Spirometry. , 1993, Thorax.
[18] D. Rapoport,et al. Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I , 2009, Pediatrics.
[19] J. Wittes,et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. , 2006, The Journal of pediatrics.
[20] J. Fulton,et al. Prediction of maximum voluntary ventilation (MVV) in African‐American adolescent girls , 1995, Pediatric pulmonology.
[21] P. Kaplan,et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. , 2008, Molecular genetics and metabolism.
[22] I. Bruce,et al. Otorhinolaryngological manifestations of the mucopolysaccharidoses. , 2005, International journal of pediatric otorhinolaryngology.
[23] G. Grimby,et al. DYNAMIC SPIROMETRY IN PATIENTS WITH TRACHEAL STENOSIS. , 2009, Acta medica Scandinavica.
[24] R. Giugliani,et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux–Lamy syndrome) , 2005, American journal of medical genetics. Part A.